Abstract：
Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown.
The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.
The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.
摘要：
目的：Empagliflozin已被证明可降低2型糖尿病患者和心力衰竭患者心血管不良结局的风险。依帕列净对急性心肌梗死（AMI）后患者的影响尚不清楚。
结果：测试Empagliflozin对急性心肌梗死患者心力衰竭住院和死亡率的影响的研究（EMPACT-MI）试验筛选了6610名AMI患者，并随机分配6522名接受依帕列净或安慰剂治疗。中位（四分位数）年龄为64（56-71）岁，75.1％的患者为男性。主要合并症包括高血压（69.1%），2型糖尿病（31.7%），既往心肌梗死（13.0%），房颤（10.9%）。大多数（74.3％）的患者出现ST段抬高型心肌梗死。总的来说,56.9％的患者有需要治疗的急性充血体征或症状，78.3％的患者有左心室收缩功能障碍，射血分数<45％。临床特征,包括基线人口统计，血运重建率，出院时的心血管药物在很大程度上与近期AMI后人群的试验相当.
结论：EMPACT-MI试验将确定empagliflozin治疗AMI患者的益处和风险。
结果：测试Empagliflozin对急性心肌梗死患者心力衰竭住院和死亡率的影响的研究（EMPACT-MI）试验筛选了6610名AMI患者，并随机分配6522名接受依帕列净或安慰剂治疗。中位（四分位数）年龄为64（56-71）岁，75.1％的患者为男性。主要合并症包括高血压（69.1%），2型糖尿病（31.7%），既往心肌梗死（13.0%），房颤（10.9%）。大多数（74.3％）的患者出现ST段抬高型心肌梗死。总的来说,56.9％的患者有需要治疗的急性充血体征或症状，78.3％的患者有左心室收缩功能障碍，射血分数<45％。临床特征,包括基线人口统计，血运重建率，出院时的心血管药物在很大程度上与近期AMI后人群的试验相当.
结论：EMPACT-MI试验将确定empagliflozin治疗AMI患者的益处和风险。
